BioNTech

BioNTech祭出10亿美元回购牌：股价深跌下的自救与肿瘤管线新叙事

BioNTech’s Board Expansion Signals Oncology Pivot — But the Market Still Wants Proof

angelina -

76欧元关口博弈：BioNTech的”数据沉默期”遇上EHA与宏观风暴

kashif hafeez -

BioNTech Caught in mRNA Sector Jolt as $590M Moderna Contract Cut Adds to Pipeline Transition Pain

BioNTech：千亿现金回购遇上德国改革暗流，肿瘤管线能否撬动估值重塑？

angelina -

BioNTech’s $1 Billion Buyback Fails to Lift Stock as German Reform Threat and Pipeline Wait Drag On

kashif hafeez -

BioNTech ASCO亮出双抗王牌：Pumitamig缓解率100%跌破眼镜，副作用比Keytruda更轻

kashif hafeez -

BioNTech’s Cancer Pivot Faces Dual Headwinds: Berlin’s Vaccine Demands and Founder Exit

BioNTech告别新冠时代：创始人2026年离场，肿瘤管线接棒

Brett Shapiro -

BioNTech’s Spinoff Deadline Nears as ASCO Data Bolster Oncology Pipeline

ASCO双刀出鞘：BioNTech肺癌双抗控制率100%，HER2 ADC冲刺审批

双拳出击：BioNTech在ASCO亮出肿瘤赛道底牌

Brett Shapiro -

BioNTech Banks on Broad Cancer Pipeline and Cost Discipline as ASCO Data Rolls In

angelina -

BioNTech’s ASCO Week: A $622 Million Loss and a Shot at a First U.S. Cancer Approval

BioNTech’s Oncology Pipeline Flexes Its Muscle: BNT323 Data Impress as Pumitamig Waits in the Wings

kashif hafeez -
1...678...15Page 7 of 15